Two ARPA‑H awards advanced regenerative efforts for lymphatic disease. A Rice University team led by Omid Veiseh secured up to $18.2 million to develop the first regenerative therapy for lymphedema focused on repairing damaged lymphatic vessels. Separately, the Georgia Institute of Technology received $21.8 million to develop a first‑of‑its‑kind therapeutic intervention targeting lymphatic disorders. Both awards signal ARPA‑H’s willingness to fund translational, high‑risk approaches in regenerative medicine and create near‑term partnering and commercialization opportunities for academic spinouts and device or biologic developers.